Monopar Therapeutics (MNPR) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Monopar Therapeutics

NasdaqCM•Healthcare•Biotechnology

$114.38-3.18(-0.03%)Pre-market

Market Cap

$866.59M

P/B

6.6x

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

How this company scores

WeakMetricSide Score: 33/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (4/25).

Profitability8/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality4/25

Strengths

Long cash runwayInterest easily coveredNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/B · 6.6x5y range 1.6x – 15.1x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $866.59M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $0
Q. Revenue: $0
TTM EBITDA: $-22.12M
TTM Op. Income: $-22.12M
Q. Op. Income: $-6.64M
TTM Net Income: $-17.84M
Q. Net Income: $-5.31M
EPS: $-0.62
Shares Out.: $8.54M

$0 in TTM revenue was flat at zero YoY, reaching $0 last quarter. TTM EBITDA of $-22.12M and TTM operating income of $-22.12M show growth is flowing through to the bottom line. However, net income is negative at $17.84M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -664466300.0%
Net Margin: -531300000.0%

Op. margin of -664466300.0% is down 341036800.0% YoY — costs are rising relative to revenue. Net margin at -531300000.0% Over the past year, operating margin is down 105% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: 6.6x

P/S of 0.0x and P/B of 6.6x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $134.98M
Cash: $52.76M
Long-Term Debt: N/A
Book Value: $130.85M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-3.25M
TTM Free Cash Flow: $-12.18M
FCF Margin: N/A
FCF / Net Income: 0.7

TTM FCF of $-12.18M on $-3.25M in operating cash flow. The FCF / Net Income ratio of 0.7x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 24% — a weakening trend.